Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7

1.

Test article concentrations in the hERG assay: losses through the perfusion, solubility and stability.

Brimecombe JC, Kirsch GE, Brown AM.

J Pharmacol Toxicol Methods. 2009 Jan-Feb;59(1):29-34. doi: 10.1016/j.vascn.2008.10.004. Epub 2008 Nov 8.

PMID:
19028590
2.

Variability in the measurement of hERG potassium channel inhibition: effects of temperature and stimulus pattern.

Kirsch GE, Trepakova ES, Brimecombe JC, Sidach SS, Erickson HD, Kochan MC, Shyjka LM, Lacerda AE, Brown AM.

J Pharmacol Toxicol Methods. 2004 Sep-Oct;50(2):93-101.

PMID:
15385083
3.

Alterations of N-methyl-D-aspartate receptor properties after chemical ischemia.

Aizenman E, Sinor JD, Brimecombe JC, Herin GA.

J Pharmacol Exp Ther. 2000 Nov;295(2):572-7.

PMID:
11046090
4.
5.

Why is the role of nitric oxide in NMDA receptor function and dysfunction so controversial?

Aizenman E, Brimecombe JC, Potthoff WK, Rosenberg PA.

Prog Brain Res. 1998;118:53-71. Review. No abstract available.

PMID:
9932434
6.

An NR2B point mutation affecting haloperidol and CP101,606 sensitivity of single recombinant N-methyl-D-aspartate receptors.

Brimecombe JC, Gallagher MJ, Lynch DR, Aizenman E.

J Pharmacol Exp Ther. 1998 Aug;286(2):627-34.

PMID:
9694913
7.

Functional consequences of NR2 subunit composition in single recombinant N-methyl-D-aspartate receptors.

Brimecombe JC, Boeckman FA, Aizenman E.

Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):11019-24.

Supplemental Content

Loading ...
Support Center